Market Reality Check

Curefoods has deferred its public listing, choosing to wait for a more receptive climate rather than push through an IPO that failed to satisfy institutional valuation expectations. This move confirms a broader shift in the Indian public markets, where investors are increasingly prioritizing bottom-line stability over pure-play growth metrics.

Following the postponement of PhonePe’s $1.3B IPO earlier this year, Curefoods’ decision underscores that SEBI approval is no longer a proxy for market readiness. Institutional investors, particularly mutual funds, are effectively resetting the ceiling for late-stage startups that have yet to demonstrate a clear path to profitability.

What Happened

The cloud kitchen operator opted to hold its listing despite securing SEBI clearance in October 2025. During recent roadshows, mutual funds signaled strong resistance to the company’s target valuation of ₹4,000 Cr ($419 Mn), viewing the premium as unjustified under current volatility. While the firm maintains it does not require immediate liquidity, the delay forces early-stage investors—including Accel, Chiratae Ventures, and Iron Pillar—to extend their hold period indefinitely.

Why It Matters

The first-order impact is a definitive signal to the late-stage ecosystem: the window for loss-making unicorns to exit at previous-round multiples has closed. For the broader market, this creates a liquidity bottleneck. If institutional players continue to push back on pricing, the “IPO pipeline” of 2025 will likely see a significant migration into either private secondary sales or bridge equity rounds.

The second-order implication is the tightening of capital allocation among growth-stage founders. Without the public market exit path, runway management becomes the primary operational KPI. Expect to see a cooling in aggressive unit expansion and a pivot toward rigorous cost-cutting to demonstrate path-to-profitability by next fiscal year.

Over the next 12-24 months, this signals a fundamental reset in venture-to-public market valuation expectations, forcing founders to accept down-rounds or structured private capital before entertaining public market entry again.

The Numbers

  • ₹4,000 Cr: Valuation sought by Curefoods during pre-IPO roadshows.
  • ₹746 Cr: Operating revenue reported for FY25, highlighting top-line growth.
  • ₹170 Cr: Net loss for FY25, the primary friction point for institutional risk profiles.
  • ₹800 Cr: Fresh capital the firm planned to raise through the primary IPO issue.

What To Watch

  • Watch for internal pressure from secondary-seeking early investors to conduct partial buybacks or private secondary exits to satisfy fund lifecycle requirements.
  • Monitor whether Curefoods pivots toward an aggressive pivot to EBITDA-positive status in FY26 to appease institutional appetites for the next cycle.
  • Track the broader IPO pipeline for similar “quality-first” delays; if high-burn startups continue to stall, expect a 6-month pause in new filings across the SaaS and D2C sectors.